Rockefeller Capital Management’s Biogen BIIB Stock Holding History
Bought
Maintained
Sold
Other funds holding BIIB
Rockefeller Capital Management's BIIB Position: Q2 2026 in Review
Rockefeller Capital Management reduced its Biogen (BIIB) stake by 9.4% in Q2 2026, selling an estimated $121K and leaving 6,128 shares worth $1.32M. The position accounts for ﹤0.01% of the portfolio, ranked #1569.
Rockefeller Capital Management first reported a position in BIIB in Q1 2018 and has held it in 26 quarters since. The position peaked at $114M in Q3 2018. 1,043 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.
- Rockefeller Capital Management held 6,128 shares of Biogen worth $1.32M as of Q2 2026.
- Rockefeller Capital Management sold 633 Biogen shares in Q2 2026, an estimated $121K.
- Biogen made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q2 2026, its #1569 holding.
- Rockefeller Capital Management first reported a position in Biogen in Q1 2018 and has held it in 26 quarters since.
- Rockefeller Capital Management's Biogen position peaked at $114M in Q3 2018.
- 1,043 funds tracked by Wall St. Rank held Biogen as of Q2 2026.
Based on Rockefeller Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.